Loading…
Calling for sickle-cell trait research, surveillance, and public education and awareness.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
71pct
3d open
vs 1,187 other HRES bills in the 115th — cohort avg 17d
Recognizes the challenges in addressing health outcomes among people with sickle-cell trait and sickle-cell disease. (Sickle-cell disease refers to blood disorders resulting from abnormal red blood cells.) Encourages the medical community to make individuals aware of their sickle-cell trait status. Urges the Department of Health and Human Services to develop a public awareness campaign regarding the importance of individuals knowing their sickle-cell trait status and to expand access for screening and counseling. Commits to supporting research on sickle-cell trait and sickle-cell disease.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2017 · fourth_quarter · Medical/Disease Research/Clinical Labs
Sickle Cell Disease/Trait Issues Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) H.Res. 539, Calling for sickle-cell trait research, surveillance, and public education and awareness Hematology/Oncology Treatment Issues General Hematology Public Health and Research Issues Clinical Trials Regulations Regulation of Laboratory Developed Tests Cancer "Moonshot" Initiative
Client expense: $30,000 · Firm income: Not reported
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2017 · fourth_quarter · Health Issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) H.Res. 539, Calling for sickle-cell trait research, surveillance, and public education and awareness S.Res. 27, Designating September 2017 as "Sickle Cell Disease Awareness Month" Cancer Drug Parity Act (H.R. 1409) Patients Access to Treatment Act (H.R. 2999) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) American Health Care Act/Better Care Reconciliation Act/Health Care Freedom Act (H.R. 1628) Graham-Cassidy-Heller-Johnson Amendment re: ACA repeal/reform Bipartisan Health Care Stabilization Act (proposed by Senators Alexander and Murray) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage Issues Impacting Coverage for Hematologic Diseases and Conditions
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2017 · third_quarter · Medical/Disease Research/Clinical Labs
Sickle Cell Disease/Trait Issues Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) H.Res. 539, Calling for sickle-cell trait research, surveillance, and public education and awareness S.Res.27, Designating September 2017 as "Sickle Cell Disease Awareness Month" Hematology/Oncology Treatment Issues General Hematology Public Health and Research Issues Clinical Trials Regulations Regulation of Laboratory Developed Tests Cancer "Moonshot" Initiative
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2017 · third_quarter · Health Issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) H.Res. 539, Calling for sickle-cell trait research, surveillance, and public education and awareness S.Res. 27, Designating September 2017 as "Sickle Cell Disease Awareness Month" Cancer Drug Parity Act (H.R. 1409) Patients Access to Treatment Act (H.R. 2999) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) American Health Care Act/Better Care Reconciliation Act/Health Care Freedom Act (H.R. 1628) Graham-Cassidy-Heller-Johnson Amendment re: ACA repeal/reform Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage Issues Impacting Coverage for Hematologic Diseases and Conditions
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
| Democratic |
| NJ |
| Dwight Evans | Democratic | PA |
| Eleanor Holmes Norton | Democratic | DC |
| Frederica S. Wilson | Democratic | FL |
| Gregory W. Meeks | Democratic | NY |
| Keith Ellison | Democratic | MN |
| Michael C. Burgess | Republican | TX |
| Raúl M. Grijalva | Democratic | AZ |
| Sheila Jackson Lee | Democratic | TX |